Mezaton solution: instructions for use. Mezaton in ampoules: instructions for use In order to narrow the vessels in the mucous membranes and to reduce the manifestations of inflammation

Instructions for use
Mezaton rr d / in. 1% 1ml №10

Dosage forms
solution for injections 1% 1ml

Synonyms
Irifrin
Irifrin BK
Nazol Baby
Nazol Kids
Neosynephrine-Pos

Group
Drugs that stimulate alpha-adrenergic receptors

International non-proprietary name
Phenylephrine

Compound
Active ingredient: Phenylephrine.

Manufacturers
Experimental plant "GNTSLS" (Ukraine), Branch "Experimental plant GNTsLS" (Ukraine)

pharmachologic effect
Vasoconstrictor. Stimulates postsynaptic alpha-adrenergic receptors. Biotransformed in the liver and gastrointestinal tract. Excreted by the kidneys as metabolites. The action begins immediately after administration and lasts for 20 (after intravenous administration) - 50 minutes (with s / c injection) - 1-2 hours (after i / m injection). The heart rate decreases, the stroke output increases, systolic and diastolic blood pressure rises, and the pulse reflexively slows down. OPSS is growing. Stimulates the brain and spinal cord. Reduces blood flow - renal, skin, in the abdominal organs and limbs, increases - coronary. Constricts pulmonary vessels and increases pressure in the pulmonary artery. As a vasoconstrictor, it has an anticongestive effect: it reduces swelling and hyperemia of the nasal mucosa, the severity of exudative manifestations, and restores free breathing; lowers pressure in the paranasal cavities and in the middle ear. Causes pupil dilation, normalizes intraocular pressure in open-angle glaucoma.

Side effect
Headache, agitation, anxiety, irritability, weakness, dizziness, hypertension, bradycardia, arrhythmia, pain in the heart area, respiratory depression, oliguria, acidosis, skin pallor, tremor, paresthesia, local ischemia of the skin at the injection site, necrosis and eschar formation when ingestion into tissues or s / c injections.

Indications for use
Subdural and inhalation anesthesia (to maintain an adequate level of blood pressure and prolong subdural anesthesia), local anesthesia (as a vasoconstrictor), acute circulatory failure, anaphylaxis, neurogenic shock, hypotension, incl. orthostatic, paroxysmal supraventricular tachycardia, reperfusion arrhythmias (Bertzold-Yarish reflex), priapism, secretory prerenal anuria, iritis, iridocyclitis.

Contraindications
Hypersensitivity, severe arterial hypertension, ventricular tachycardia, tendency to angiospasms, bradycardia, shock in myocardial infarction, decompensated heart failure, conduction disturbances, severe atherosclerosis, severe coronary artery disease, cerebral artery disease, arterial hypertension, acute pancreatitis and hepatitis, hyperthyroidism, peripheral thrombosis and mesenteric arteries, prostatic hypertrophy, pregnancy, children (up to 15 years) and old age.

Method of application and dosage
In case of an acute decrease in blood pressure, it is administered intravenously at a dose of 0.1 - 0.3 - 0.5 ml of a 1% solution in 40 ml of glucose solution or isotonic sodium chloride solution. Drop injected 1 ml of 1% solution in 250 - 500 ml of glucose solution. Under the skin or intramuscularly, 0.3 - 1 ml of a 1% solution is prescribed (for adults). The highest single doses for adults under the skin and intramuscularly: single - 0.01 g, daily - 0.05 g, into a vein: single - 0.005 g, daily - 0.025 g.

Overdose
Manifested by ventricular extrasystole and short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure. Treatment: intravenous administration of alpha-blockers (for example, phentolamine) and beta-blockers (for rhythm disturbances).

Interaction
Oxytocin, MAO inhibitors, tricyclic antidepressants, ergot alkaloids, sympathomimetics increase the pressor effect, and the latter also increase arrhythmogenicity. Alpha-blockers (phentolamine), phenothiazines, furosemide and other diuretics prevent vasoconstriction. Beta-blockers neutralize cardiostimulating activity, against the background of reserpine, arterial hypertension is possible (due to the depletion of catecholamine reserves in adrenergic neurons, sensitivity to sympathomimetics increases).

special instructions
To stimulate labor, it is not recommended to use in combination with oxytocin-containing drugs (possible severe persistent hypertension and damage to cerebral vessels with the development of hemorrhagic stroke in the postpartum period). During the treatment period, ECG, blood pressure, wedge pressure in the pulmonary artery, cardiac output, blood circulation in the extremities and at the injection site should be monitored. With arterial hypertension, it is necessary to maintain the SBP at a level of 30-40 mm Hg. below usual. Before or during therapy, correction of hypovolemia, hypoxia, acidosis, hypercapnia is required. A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent arrhythmias require discontinuation of treatment. To prevent a re-lowering of blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after prolonged infusion. The infusion is resumed if the SBP drops to 70-80 mm Hg. During therapy, potentially hazardous activities that require speed of motor and mental reactions are excluded.

Storage conditions
List B. In a dark place.

In 1 ml eye drops contains 25 mg of phenylephrine (in the form of hydrochloride), which, in terms of 100% of the substance, is 25 mg. Auxiliary are decamethoxin, , disodium edetate, purified water.

In 1 ml solution, intended for injection, contains 10 mg of phenylephrine (in the form of hydrochloride) and auxiliary compounds: glycerin and injection. water.

Release form

Eye drops of 5 ml in dropper bottles, as well as another form of release - in the form of a solution for injection, which is available in ampoules (1 ml in volume), packed 10 ampoules in cardboard packs, equipped with an ampoule scarifier or a cutting ceramic disc.

pharmachologic effect

Pharmacological group of the drug: α-agonists. In addition, Mezoton is characterized by a vasoconstrictor effect.

Pharmacodynamics and pharmacokinetics

Mezaton (INN Phenylephrine) known α-adrenergic stimulant , which has little effect on β-adrenergic receptors located in the heart. Is not catecholamine , since it has only one hydroxyl group in its aromatic nucleus, it is able to constrict arterioles and increase blood pressure, which can lead to the development of reflex bradycardia. Compared to norepinephrine or increases blood pressure not so sharply and acts much longer due to the fact that it is less exposed to catechol-O-methyltransferase . Therapy with Mezaton does not lead to an increase in the minute volume of blood. The drug exhibits a vasoconstrictor effect, similar, however, less pronounced and longer, while it practically does not have a chronotropic and inotropic effect on the heart.

After instillation, the dilator of the pupil is reduced, which causes its expansion, and the smooth muscles of the arterioles of the conjunctiva. There is no effect on the ciliary muscle, because mydriasis observed without cycloplegia .

The therapeutic effect occurs immediately after intravenous administration and is observed over the next 5-20 minutes, with the subcutaneous route of administration - 50 minutes, intramuscular - 60-120 minutes.

Information about pharmacokinetics

Phenylephrine is able to easily penetrate into the tissues of the eye, expanding the pupils within 10-60 minutes. Due to a significant reduction in the dilator of the pupils, 30-45 minutes after instillation, particles of the pigment of the iris leaf can be determined in the moisture of the anterior chamber of the eye, which requires differentiation uveitis or getting blood cells into the moisture of the anterior chamber.

Metabolism phenylephrine occurs in the liver, as well as the gastrointestinal tract (without the participation of the enzyme - catechol-O-methyltransferase ). Excretion of metabolites is provided by the kidneys.

Indications for the use of Mezaton

Application in ophthalmology

• , anterior uveitis (treatment and prevention of posterior adhesions, asthenopia , reducing exudation from the iris);
• pupil dilation for diagnostic purposes ophthalmoscopy and other procedures necessary to determine the condition of the posterior part of the eye, as well as for laser interventions and vitreo-retinal surgery;
• for provocative testing in people with a narrow anterior chamber angle profile and suspected closed-angle ;
• differential diagnosis of the type of injection of the eyeball;
• reduction of hyperemia and irritation with red eye syndrome ;
• complex treatment spasm of accommodation in children.

For parenteral use

• arterial hypotension ;
• shock (including traumatic and toxic shock );
• vascular form of insufficiency, which can also occur with an overdose of vasodilators;
• as a local vasoconstrictor.

For intranasal use

• or .

Contraindications

• pheochromocytoma ;
• hypertrophy in obstructive cardiomyopathy;
• ventricular fibrillation;
• hypersensitivity to components.

Use in ophthalmology is contraindicated:

• with narrow-angle or closed-angle glaucoma;
• if there are significant disorders of the cardiovascular system (including heart disease, hypertension , );
• at insulin dependent ;
• at ;
• the presence of violations of the integrity of the fundus or violations of the function of tear secretion, congenital deficiency of glucose-6-phosphate hydrogenase , hepatic porphyria ;

The use of Mezoton with caution is possible

• at metabolic acidosis ;
• at hypercapnia ;
• at hypoxia ;
• at ;
• at arterial hypertension , as well as hypertension in the small circle of the circulatory system;
• at hypovolemia ;
• with severe aortic stenosis ;
• with acute;
• at tachyarrhythmias and ventricular ;
• with occlusive vascular disease (including history): arterial thromboembolism , thromboangiitis obliterans (Buerger's disease ), Raynaud's disease , the tendency of blood vessels to spasms, as well as with frostbite, with diabetic endarteritis , , the combined use of monoamine oxidase inhibitors;
• when using the general (halothane ), impaired renal function;
• in the elderly or childhood (≤ 18 years).

Attention! Mezaton in the form of eye drops can be used in pediatrics - with the exception of newborns with low body weight.

Side effects

• increase in blood pressure;
• ventricular fibrillation;
• heartbeat;
• arrhythmia ;
• bradycardia ;
• dizziness;
• feeling of fear;
• weakness;
• anxiety;
• headache;
• hemorrhage in the brain;
• tremor ;
• convulsions;
• pale skin of the face;
• local formation of a scab when it enters the tissue;
• skin at the injection site;
• allergic reactions.

Possible adverse reactions from the organs of vision when used in ophthalmology

Burning, reactive hyperemia, blurred vision, irritation, discomfort, increased intraocular pressure, lacrimation, reactive miosis .

Application instruction of Mezaton (Way and dosage)

Intravenous or jet administration injection solution recommended to be done slowly.

In a state of collapse

• Mezaton ampoules, instructions for use for intravenous drip administration: use 1 ml of a 1% solution diluted in 250 or 500 ml of a 5% solution.
• 0.1 / 0.3 / 0.5 ml of a 1% solution should be diluted in 20 ml of a 5% dextrose solution or a 0.9% sodium chloride solution. If necessary, repeat the introduction.
• Dosage for subcutaneous or intramuscular use in adult patients - from 0.3 to 1 ml of a 1% solution up to 2-3 times a day; for children from 15 years old (with arterial hypotension ) at spinal anesthesia - from 0.5 to 1 mg per 1 kg of the child's body weight.

In order to narrow the vessels in the mucous membranes and to reduce the manifestations of inflammatory phenomena

It is necessary to lubricate or instill the drug concentrate. solution
- 0,125/ 0,25 /0,5/1%.

For local anesthesia

The maximum allowable dose for adults: single dose for subcutaneous and intramuscular injection - no more than 10 mg, daily dose - no more than 50 mg, for intravenous administration: single dose is up to 5 mg, daily dose - 25 mg.

Attention!

In order to prevent a repeated decrease in blood pressure associated with the withdrawal of the drug, the dose is reduced gradually, especially after a long infusion. Infusions can be resumed if it was possible to reduce the system. BP up to 70–80 mm Hg.

Overdose

Clinical picture

Developing ventricular extrasystole , short paroxysmal manifestations ventricular tachycardia , "heaviness" of the head and limbs, a significant increase in blood pressure.

Treatment activities

In / in the introduction α-blockers (for example, ). If cardiac arrhythmias are observed, it is advisable to use β-blockers .

Interaction

Drug interaction reactions are observed when therapy is combined with the following drugs:

• With diuretics and antihypertensive agents - the antihypertensive effect of diuretic and antihypertensive drugs is reduced, for example: Guanadrela , Guanethidine , Methyldopa , mecamylamine .
• With phenothiazines, α-blockers ( Phentolamine ) reduces the hypertensive effect.
• With MAO Inhibitors, for example, with, Procarbazine , Selegiline , as well as , ergot alkaloids , tricyclic antidepressants, Methylphenidate , adrenostimulants - there is a significant increase in the pressor effect and arrhythmogenicity of phenylephrine.
• With β-blockers, cardiostimulating activity decreases, with it is possible to develop arterial hypertension, which occurs due to depletion of the depot of catecholamines localized in adrenergic endings, which increases the response to adrenomimetics.
• With inhalation anesthetics (, enflurane , Halothane , Isoflurane , Methoxyflurane ) increases the likelihood of severe atrial, as well as ventricular arrhythmias due to a sharp increase in the sensitivity of the myocardium to drugs - sympathomimetics.
• FROM , Methylergometrine , oxytocin , Doxapram - the severity of the vasoconstrictor effect increases.
• FROM nitrates - their antianginal effect decreases, which subsequently leads to a decrease in the pressor effect of sympathomimetics and the risk of developing arterial hypotension .
• FROM thyroid hormones there is a mutual potentiation of effects and the risk of coronary insufficiency, which is aggravated by coronary atherosclerosis .
• Mydriatic influence phenylephrine increases under the influence of .

Terms of sale

Recipe needed (in Latin) Recipe: Mesatonum).

Storage conditions

• protected place from the rays of light;
• temperature not more than +25 °C.

Storage should be carried out in a place inaccessible to young children.

Best before date

The shelf life of the drug Mezaton eye drops is different and is - no more than 2 years, an opened dropper bottle - up to 2 weeks.

special instructions

During therapy, it is necessary to control the parameters of the extremities ECG, blood pressure, minute volume of blood flow, blood circulation in the extremities and at the injection site.

At the beginning and during the course of shock therapy, correction is necessary hypoxia , hypercapnia , hypovolemia and acidosis .

During the use of Mezaton, it is recommended to refrain from driving a car, and other activities that require high speed, motor and mental reactions, as well as other dangerous activities (managing complex mechanisms, working with machines).

During pregnancy and lactation

Therapy is possible with caution: only according to strict prescriptions and under the supervision of the attending physician, who objectively assessed the balance of benefits and risks for the mother, fetus, unborn child. In addition, it has been established that the use of vasoconstrictors during labor to correct arterial hypotension, as well as additives to local anesthetics against the background of such drugs that can stimulate uterine contractility (for example:, Methylergometrine , Ergotamine , Ergometrine ), can lead to a persistent increase in blood pressure in the postpartum period.

Analogues

• 2.5%, (approximate price from 450 rubles);
• spray, Germany (approximate price from 150 rubles).

Compound

pharmachologic effect

Indications for use

Mode of application

Side effects

Pregnancy

drug interaction

Overdose

Release form

Storage conditions

Synonyms

Additionally

Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide on the appointment of the drug, as well as determine the dose and methods of its use.

| Mesaton

Analogues (generics, synonyms)

Vizofrin, Nazol Baby, Nazol Kids, Neosynephrine-POS, Phenylephrine Hydrochloride, Aurora Hot Sip, Adzhikold, Adrianol, Aidrink, Axagripp, Alergomax, Amitsitron, Anacold, Anticatarrhal, Antiflu, Appamid Plus, Aspirin Complex, Astrcitron, Bronchoril, Vibrocil, Vokasept , Glycodin, Gripout, y Gripgo, Gripcold-N, Griposan, Griposan Plus, Griposan Hot, Gripflu, Influnorm, Irifrin, Coldrin, Coldflu Extra, Coldfree, Combigripp, Combinex, Combinex-P, Loraine, Lorcold, Maxicold, Midrimax, Neogrip , Neoflu 750, Nolgripp, Parafex, Prostudox, Radikold Plus, Rankof, Relief, Rinza, Rinicold, Pharmacitron, Flucoldex forte, Citrik

Recipe (international)

Rp.: Sol. Mesatoni 1% 1ml
D.t. d. N. 10 ampull.
S. Dissolve the contents of the ampoule in 40 ml of 40% glucose solution. Enter intravenously, slowly.

Rp.: Sol. Mesatoni 1% 1ml
D.t. d. N. 10 ampull.
S. Inject under the skin or intramuscularly 0.5-1 ml.

Rp.: Sol. Mesatoni 1% 5ml
D.S. Eye drops. 1-2 drops per day in both eyes.

Rp.: Sol. Mesatoni 0.25% 10ml
D.S. Nose drops.

Recipe (Russia)

Prescription form - 107-1 / y

Active substance

Phenylephrine (Phenylephrine)

pharmachologic effect

Alpha1-adrenergic stimulant, which has little effect on the beta-adrenergic receptors of the heart. It is not a catecholamine (it contains only one hydroxyl group in the aromatic nucleus). It causes narrowing of arterioles and an increase in blood pressure (with possible reflex bradycardia). Compared with norepinephrine and epinephrine, it increases blood pressure less sharply, but acts more long-term (weaker affected by catechol-O-methyltransferase). Does not cause an increase in minute blood volume.
The action begins immediately after administration and lasts for 5-20 minutes (after i / v administration), 50 minutes (with subcutaneous administration), 1-2 hours (after i / m administration). Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys as metabolites.

Mode of application

For adults: Intravenously slowly, with collapse - 0.1-0.3-0.5 ml of a 1% solution, diluted in 20 ml of a 5% dextrose solution or 0.9% sodium chloride solution. If necessary, the introduction is repeated.
Intravenous drip - 1 ml of a 1% solution in 250-500 ml of a 5% dextrose solution. Subcutaneously or intramuscularly, adults - 0.3-1 ml of 1% solution 2-3 times a day; children over 15 years of age with arterial hypotension during spinal anesthesia - 0.5-1 mg / kg.

To narrow the vessels of the mucous membranes and reduce inflammation, lubricate or instill (solution concentration - 0.125%, 0.25%, 0.5%, 1%).
With local anesthesia, 0.3-0.5 ml of a 1% solution is added per 10 ml of an anesthetic solution.

Higher doses for adults: subcutaneously and intramuscularly: single - 10 mg, daily - 50 mg; intravenously: single - 5 g, daily - 25 mg.

Indications

Parenterally:
- arterial hypotension;
- shock conditions (including traumatic, toxic);
- vascular insufficiency (including against the background of an overdose of vasodilators);
- as a vasoconstrictor during local anesthesia.

Intranasally:

- vasomotor and allergic rhinitis.

Contraindications

- hypersensitivity to the drug;
- hypertrophic obstructive cardiomyopathy;
- pheochromocytoma;
- ventricular fibrillation.
- metabolic acidosis
- hypercapnia
- hypoxia
- atrial fibrillation
- angle-closure glaucoma, arterial hypertension
- hypertension in the pulmonary circulation
- hypovolemia
- severe aortic stenosis
- acute myocardial infarction
- tachyarrhythmia
- ventricular arrhythmia
- occlusive vascular diseases (including history) - arterial thromboembolism atherosclerosis
thromboangiitis obliterans (Buerger's disease)
- Raynaud's disease
- the tendency of blood vessels to spasms (including with frostbite)
- diabetic endarteritis
thyrotoxicosis, diabetes mellitus
- porphyria
- deficiency of glucose-6-phosphate dehydrogenase
- combined use of monoamine oxidase inhibitors
- under general anesthesia (halothane)
- impaired renal function
- elderly age
- age up to 18 years (efficacy and safety have not been established).

Side effects

- From the side of the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.
- From the side of the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage.
- Other: pallor of the skin of the face, ischemia of the skin at the injection site, in isolated cases, necrosis and the formation of a scab are possible when it enters the tissues or when injected subcutaneously, allergic reactions.

Release form

Solution for injections. 10 mg/1 ml: amp. 10 pieces.
Solution for injection 1 ml
phenylephrine hydrochloride 10 mg
1 ml - ampoules (10) - packs of cardboard.

ATTENTION!

The information on the page you are viewing was created for informational purposes only and does not promote self-treatment in any way. The resource is designed to familiarize healthcare professionals with additional information about certain medicines, thereby increasing their level of professionalism. The use of the drug "" without fail provides for a consultation with a specialist, as well as his recommendations on the method of application and dosage of the medicine you have chosen.

Alpha agonist

Active substance

Phenylephrine hydrochloride (phenylephrine)

Release form, composition and packaging

1 ml - ampoules (10) - packs of cardboard.

pharmachologic effect

Alpha1-adrenergic stimulant, which has little effect on the beta-adrenergic receptors of the heart; is not a catecholamine (contains only one hydroxyl group in the aromatic nucleus). Causes narrowing of arterioles and increased blood pressure (with possible reflex bradycardia). Compared with and epinephrine, it increases blood pressure less sharply, but acts more long-term (less susceptible to the action of catechol-O-methyltransferase); does not cause an increase in the minute volume of blood.

The action begins immediately after administration and lasts for 5-20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular administration).

Pharmacokinetics

Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys as metabolites.

Indications

Parenterally:

• arterial hypotension;
• shock conditions (including traumatic, toxic);
• vascular insufficiency (including against the background of an overdose of vasodilators);
• as a vasoconstrictor during local anesthesia.

Intranasally:

• vasomotor and allergic rhinitis.

Contraindications

• hypersensitivity to the drug;
• hypertrophic obstructive cardiomyopathy;
• pheochromocytoma;
• ventricular fibrillation.

Carefully:

Metabolic acidosis, hypercapnia, hypoxia, angle-closure glaucoma, arterial hypertension, hypertension in the pulmonary circulation, hypovolemia, severe aortic stenosis, acute myocardial infarction, tachyarrhythmia, ventricular arrhythmia, occlusive vascular disease (including history) - arterial thromboembolism , atherosclerosis, thromboangiitis obliterans (Buerger's disease), Raynaud's disease, the tendency of vessels to spasm (including frostbite), diabetic endarteritis, thyrotoxicosis, diabetes mellitus, porphyria, glucose-6-phosphate dehydrogenase deficiency, the combined use of monoamine oxidase inhibitors, with general anesthesia (halothane), impaired renal function, old age, age up to 18 years (efficacy and safety have not been established).

Dosage

Intravenously slowly, with collapse - 0.1-0.3-0.5 ml of a 1% solution, diluted in 20 ml of a 5% dextrose solution or a 0.9% solution. If necessary, the introduction is repeated.

Intravenous drip - 1 ml of a 1% solution in 250-500 ml of a 5% dextrose solution.

subcutaneously or intramuscularly, adults- 0.3-1 ml of 1% solution 2-3 times a day; children over 15 years old at arterial hypotension during spinal anesthesia- 0.5-1 mg/kg.

For constriction of the vessels of the mucous membranes and reduce inflammation lubricate or instill (solution concentration - 0.125%, 0.25%, 0.5%, 1%).

At local anesthesia add 0.3-0.5 ml of 1% solution per 10 ml of anesthetic solution.

Higher doses for adults: subcutaneously and intramuscularly: single - 10 mg, daily - 50 mg; intravenously: single - 5 mg, daily - 25 mg.

Side effects

From the side of the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.

From the side of the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage.

Others: pallor of the skin of the face, ischemia of the skin at the injection site, in isolated cases, necrosis and the formation of a scab are possible when it enters the tissues or with subcutaneous injections, allergic reactions.

Overdose

Symptoms: ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.

Treatment: intravenous administration of alpha-blockers (phentolamine) and (for cardiac arrhythmias).

drug interaction

Mezaton reduces the antihypertensive effect of diuretics and antihypertensive drugs (methyldopa, mecamylamine, guanadrel, guanethidine).

Phenothiazines, alpha-blockers (phentolamine), and other diuretics reduce the hypertensive effect.

Monoamine oxidase inhibitors (furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the pressor effect and arrhythmogenicity of phenylephrine.

Beta-blockers reduce cardiostimulating activity, against the background of reserpine, arterial hypertension is possible (as a result of depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases). Inhalation drugs (chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias, as they dramatically increase myocardial sensitivity to sympathomimetics.

Ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.
Reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of sympathomimetics and the risk of arterial hypotension (simultaneous use is possible, depending on the achievement of the desired therapeutic effect).

Thyroid hormones increase (mutually) the effect and the associated risk of coronary insufficiency (especially in coronary atherosclerosis).

special instructions

During the treatment period, ECG, blood pressure, minute blood volume, blood circulation in the extremities and at the injection site should be monitored.

In patients with arterial hypertension in the event of drug-induced collapse, it is sufficient to maintain systolic blood pressure at a level lower than usual by 30-40 mm Hg.

Before or during the treatment of shock conditions, correction of hypovolemia, hypoxia, acidosis and hypercapnia is mandatory.

A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.

To prevent a re-lowering of blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after prolonged infusion.

The infusion is resumed if systolic blood pressure drops to 70-80 mm Hg.

It should be borne in mind that the use of vasoconstrictors during childbirth to correct arterial hypotension or as additives to local anesthetics against the background of drugs that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) can lead to a persistent increase in blood pressure in the postpartum period.

With age, the number of adrenoreceptors sensitive to phenylephrine decreases. Monoamine oxidase inhibitors, increasing the pressor effect of sympathomimetics, can cause headaches, arrhythmias, vomiting, hypertensive crisis, therefore, when patients take monoamine oxidase inhibitors in the previous 2-3 weeks, the doses of sympathomimetics should be reduced.

Influence on the ability to drive vehicles and control mechanisms

During therapy, one should not engage in hazardous activities that require the speed of motor and mental reactions (including driving a car).

Pregnancy and lactation

Adequate and strictly controlled studies in humans and animals on the effect of the drug on pregnant women have not been conducted, there are no data on the release of the drug into breast milk, on the basis of which the use of the drug during pregnancy and during breastfeeding is possible with caution, only under strict indications and under medical supervision assessing the benefit/risk ratio.

Terms and conditions of storage

Store in a place protected from light and out of the reach of children at a temperature not exceeding 25°C. Shelf life - 3 years.